British Biotech CellCentric Expands to Boston, Advancing Late-Stage Clinical Development

CellCentric, a British biotechnology company, has announced its expansion into the United States with the opening of a new office in Boston. This strategic move comes as the company's lead asset, inobrodib, progresses towards late-stage clinical development for multiple myeloma and other indications.

U.S. Expansion and Talent Acquisition

The Boston office will serve as a key hub for CellCentric's international operations, focusing on accelerating inobrodib's development through accelerated approval and phase 3 studies. Andy Fergus, CellCentric's Chief Development Officer, highlighted Boston's status as a global biotechnology hub, making it an ideal location for advancing inobrodib's development.

CellCentric is actively recruiting experienced professionals in later-stage multiple myeloma drug development, including specialists in regulatory affairs, clinical data management, statistics, and program management. The company also plans to hire a new chief business officer and chief financial officer based in the United States, further strengthening its executive team.

Inobrodib: A Promising Candidate for Multiple Myeloma

Inobrodib, CellCentric's lead asset, is an oral small molecule targeting p300 and CREB-binding protein, both transcriptional regulators linked to cancer. The drug candidate received orphan drug designation for multiple myeloma from the FDA in June 2023.

Currently, inobrodib is being evaluated in phase 1/2 trials for blood cancers, including multiple myeloma, as well as advanced solid tumors. In addition to multiple myeloma, CellCentric is pursuing inobrodib's potential in acute myeloid leukemia, lymphomas, and solid tumors.

Strategic Importance of U.S. Presence

Despite recent changes in U.S. scientific research and federal health infrastructure under the Trump administration, CellCentric emphasizes the importance of establishing a presence in the United States. The company views the U.S. as its primary clinical and commercial market, making this expansion crucial for its long-term success.

The move to Boston allows CellCentric to leverage the region's strong talent pool and biotechnology ecosystem, positioning the company for growth as it advances its pipeline and pursues late-stage clinical development.